$Alemtuzumab in the treatment of fludarabine refractory B-cell chronic lymphocytic leukemia (CLL)$
Código QR

Alemtuzumab in the treatment of fludarabine refractory B-cell chronic lymphocytic leukemia (CLL)

Marco Montillo, Francesca Ricci, Sara Miqueleiz, Alessandra Tedeschi, Enrica MorraDepartment of Oncology/Hematology, Division of Hematology and Bone Marrow Transplant Unit, Niguarda Ca&rsquo; Granda Hospital, Milan, ItalyAbstract: The introduction of immunotherapeutic agents has provided ren...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Marco Montillo, Francesca Ricci, Sara Miqueleiz, Alessandra Tedeschi, Enrica Morra
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2008
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/8fca0c3e95b34ce59ae258549396da98
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:8fca0c3e95b34ce59ae258549396da98
record_format	dspace
spelling	oai:doaj.org-article:8fca0c3e95b34ce59ae258549396da982021-12-02T02:46:08ZAlemtuzumab in the treatment of fludarabine refractory B-cell chronic lymphocytic leukemia (CLL)1177-54751177-5491https://doaj.org/article/8fca0c3e95b34ce59ae258549396da982008-03-01T00:00:00Zhttp://www.dovepress.com/alemtuzumab-in-the-treatment-of-fludarabine-refractory-b-cell-chronic--a52https://doaj.org/toc/1177-5475https://doaj.org/toc/1177-5491Marco Montillo, Francesca Ricci, Sara Miqueleiz, Alessandra Tedeschi, Enrica MorraDepartment of Oncology/Hematology, Division of Hematology and Bone Marrow Transplant Unit, Niguarda Ca&rsquo; Granda Hospital, Milan, ItalyAbstract: The introduction of immunotherapeutic agents has provided renewed hope for Chronic lymphocytic leukemia fludarabine-refractory patients. Several clinical trials have shown that alemtuzumab is a more effective option compared to combination chemotherapy for treatment of patients who have relapsed or who are refractory to fludarabine, including those with poor prognostic factors. Although there are significant potential toxicities associated with alemtuzumab, such as infusional reactions and the risk of cytomegalovirus (CMV) reactivation, most are manageable. Pre-treatment anti-pyretics and anti-histamines are recommended to prevent or mitigate the acute infusional reactions associated with intravenous infusion. Recent use of alemtuzumab via the subcutaneous route has been shown to be well tolerated and has yielded similar response rates to the infusional method of administration. Prophylaxis with thrimethoprim/sulphamethoxazole (TMP/SMZ) as well as valacyclovir or a similar anti-viral can prevent many of the opportunistic infections seen in early trials. Reactivation of CMV infection can be effectively managed with monitoring and early treatment. Chemo-immunotherapy combination with alemtuzumab has been tested and demonstrated unprecedented clinical results in relapsed and refractory patients. The use of this agent earlier in the algorithm of patients with these characteristics should be considered. Future areas of research will include the use of alemtuzumab in combination with other monoclonal antibodies and other targeted therapies.Keywords: chronic lymphocytic leukemia, fludarabine, alemtuzumab Marco MontilloFrancesca RicciSara MiqueleizAlessandra TedeschiEnrica MorraDove Medical PressarticleMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2008, Iss Issue 1, Pp 41-52 (2008)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Marco Montillo Francesca Ricci Sara Miqueleiz Alessandra Tedeschi Enrica Morra Alemtuzumab in the treatment of fludarabine refractory B-cell chronic lymphocytic leukemia (CLL)
description	Marco Montillo, Francesca Ricci, Sara Miqueleiz, Alessandra Tedeschi, Enrica MorraDepartment of Oncology/Hematology, Division of Hematology and Bone Marrow Transplant Unit, Niguarda Ca&rsquo; Granda Hospital, Milan, ItalyAbstract: The introduction of immunotherapeutic agents has provided renewed hope for Chronic lymphocytic leukemia fludarabine-refractory patients. Several clinical trials have shown that alemtuzumab is a more effective option compared to combination chemotherapy for treatment of patients who have relapsed or who are refractory to fludarabine, including those with poor prognostic factors. Although there are significant potential toxicities associated with alemtuzumab, such as infusional reactions and the risk of cytomegalovirus (CMV) reactivation, most are manageable. Pre-treatment anti-pyretics and anti-histamines are recommended to prevent or mitigate the acute infusional reactions associated with intravenous infusion. Recent use of alemtuzumab via the subcutaneous route has been shown to be well tolerated and has yielded similar response rates to the infusional method of administration. Prophylaxis with thrimethoprim/sulphamethoxazole (TMP/SMZ) as well as valacyclovir or a similar anti-viral can prevent many of the opportunistic infections seen in early trials. Reactivation of CMV infection can be effectively managed with monitoring and early treatment. Chemo-immunotherapy combination with alemtuzumab has been tested and demonstrated unprecedented clinical results in relapsed and refractory patients. The use of this agent earlier in the algorithm of patients with these characteristics should be considered. Future areas of research will include the use of alemtuzumab in combination with other monoclonal antibodies and other targeted therapies.Keywords: chronic lymphocytic leukemia, fludarabine, alemtuzumab
format	article
author	Marco Montillo Francesca Ricci Sara Miqueleiz Alessandra Tedeschi Enrica Morra
author_facet	Marco Montillo Francesca Ricci Sara Miqueleiz Alessandra Tedeschi Enrica Morra
author_sort	Marco Montillo
title	Alemtuzumab in the treatment of fludarabine refractory B-cell chronic lymphocytic leukemia (CLL)
title_short	Alemtuzumab in the treatment of fludarabine refractory B-cell chronic lymphocytic leukemia (CLL)
title_full	Alemtuzumab in the treatment of fludarabine refractory B-cell chronic lymphocytic leukemia (CLL)
title_fullStr	Alemtuzumab in the treatment of fludarabine refractory B-cell chronic lymphocytic leukemia (CLL)
title_full_unstemmed	Alemtuzumab in the treatment of fludarabine refractory B-cell chronic lymphocytic leukemia (CLL)
title_sort	alemtuzumab in the treatment of fludarabine refractory b-cell chronic lymphocytic leukemia (cll)
publisher	Dove Medical Press
publishDate	2008
url	https://doaj.org/article/8fca0c3e95b34ce59ae258549396da98
work_keys_str_mv	AT marcomontillo alemtuzumabinthetreatmentoffludarabinerefractorybcellchroniclymphocyticleukemiacll AT francescaricci alemtuzumabinthetreatmentoffludarabinerefractorybcellchroniclymphocyticleukemiacll AT saramiqueleiz alemtuzumabinthetreatmentoffludarabinerefractorybcellchroniclymphocyticleukemiacll AT alessandratedeschi alemtuzumabinthetreatmentoffludarabinerefractorybcellchroniclymphocyticleukemiacll AT enricamorra alemtuzumabinthetreatmentoffludarabinerefractorybcellchroniclymphocyticleukemiacll
_version_	1718402178033385472

Alemtuzumab in the treatment of fludarabine refractory B-cell chronic lymphocytic leukemia (CLL)

Ejemplares similares